MUC2 Cancer Research Results

MUC2, Mucin 2, oligomeric mucus/gel-forming: Click to Expand ⟱
Source:
Type:

MUC2 is the dominant intestinal gel-forming mucin and directly affects mucus barrier integrity, inflammation, microbiome interaction, colorectal cancer biology, immune exclusion, and drug penetration. Recent CRC work reports that MUC2 can act as a physical barrier limiting immune infiltration, and reviews describe mucin-rich barriers as contributing to immune evasion and therapy resistance.
Scientific Papers found: Click to Expand⟱
6462- 1,8-Cin,    Modes of Action of 1,8-Cineol in Infections and Inflammation
- Review, Var, NA - Review, AD, NA
*BioAv↑, *BBB↑, *AntiViral↑, *Bacteria↓, *AntiFungal↑, *Inflam↓, *BioAv↑, *MUC2↓, *MUC19↓, *NF-kB↓, *ICAM-1↓, *VCAM-1↓, DNAdam↑, *lipid-P↓, *PGE2↓, *IL4↓, *IL6↓, *IL1β↓, *IL6↓, Synergy↑, TGF-β↓, fascin↓, VEGF↓, MMP9↓, *MAPK↓, *ERK↓, JNK↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↑, *neuroP↑, *GSK‐3β↓, *AGEs↓, *BBB↑, *NLRP3↓,
9054- PatchO,    Patchouli Alcohol: a Natural Sesquiterpene Against Both Inflammation and Intestinal Barrier Damage of Ulcerative Colitis
- in-vivo, Col, NA
*TNF-α↓, *IFN-γ↓, *IL1β↓, *IL6↓, *IL17↓, *iNOS↓, *COX2/PTGS2↓, *TJ↑, *ZO-1↑, *CLDN1↑, *OCLN↑, *MUC1↑, *MUC2↑, *Inflam↓, *IBI↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

GSK‐3β↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

JNK↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Wnt↓, 1,  

Migration(tgid=13) ⓘ

fascin↓, 1,   MMP9↓, 1,   TGF-β↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Synergy↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

lipid-P↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GSK‐3β↓, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

ERK↓, 1,   MAPK↓, 1,  

Migration(tgid=13) ⓘ

MUC1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VCAM-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,   CLDN1↑, 1,   IBI↑, 1,   MUC19↓, 1,   MUC2↓, 1,   MUC2↑, 1,   OCLN↑, 1,   TJ↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL17↓, 1,   IL1β↓, 2,   IL4↓, 1,   IL6↓, 3,   Inflam↓, 2,   NF-kB↓, 1,   NLRP3↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 35

Scientific Paper Hit Count for: MUC2, Mucin 2, oligomeric mucus/gel-forming
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1493  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page